Literature DB >> 18060332

[Female patient with organic psychosyndrome and neurological focal signs after immunosuppressant therapy].

P Kühnlein1, M Ringhoffer, H Tumani, H J Gdynia.   

Abstract

Cerebral toxoplasmosis nearly exclusively affects immunodeficient or immunocompromised patients. Mostly, it is a reactivation of latent toxoplasmosis. The pathogens, persisting in the reticuloendothelial system of heart and skeletal muscle cells, are causing a multifocal necrotizing encephalitis. The characteristic clinical features are organic psychosyndrome and focal neurological signs such as monoparesis, hemiparesis, aphasia, or seizures. Here we describe a 56-years-old patient who developed cerebral toxoplasmosis after receiving stem-cell transplantation treatment for acute myeloic leukemia, and we discuss the clinical features, differential diagnoses and therapeutic strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18060332     DOI: 10.1007/s00108-007-1983-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  13 in total

1.  Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  R Martino; S Bretagne; M Rovira; A J Ullmann; J Maertens; T Held; E Deconinck; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2000-05       Impact factor: 5.483

2.  Survival of persons with and without HIV infection in Denmark, 1995-2005.

Authors:  Nicolai Lohse; Ann-Brit Eg Hansen; Gitte Pedersen; Gitte Kronborg; Jan Gerstoft; Henrik Toft Sørensen; Michael Vaeth; Niels Obel
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

3.  Neural tube defect surveillance and folic acid intervention--Texas-Mexico border, 1993-1998.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-01-14       Impact factor: 17.586

4.  Detection of Toxoplasma gondii in the spinal fluid of a bone marrow transplant recipient.

Authors:  M A Fisher; J Levy; M Helfrich; C S August; S E Starr; B J Luft
Journal:  Pediatr Infect Dis J       Date:  1987-01       Impact factor: 2.129

5.  Value of the polymerase chain reaction for the detection of Toxoplasma gondii in cerebrospinal fluid from patients with AIDS.

Authors:  E Schoondermark-van de Ven; J Galama; C Kraaijeveld; J van Druten; J Meuwissen; W Melchers
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079

6.  Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team.

Authors:  P H Chandrasekar; F Momin
Journal:  Bone Marrow Transplant       Date:  1997-04       Impact factor: 5.483

Review 7.  Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review.

Authors:  F Derouin; A Devergie; P Auber; E Gluckman; B Beauvais; Y J Garin; M Lariviere
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

8.  Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience.

Authors:  M A Slavin; J D Meyers; J S Remington; R C Hackman
Journal:  Bone Marrow Transplant       Date:  1994-05       Impact factor: 5.483

9.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

Authors:  Christoph Schmid; Michael Schleuning; Rainer Schwerdtfeger; Bernd Hertenstein; Eva Mischak-Weissinger; Donald Bunjes; Stephanie V Harsdorf; Christoph Scheid; Udo Holtick; Hildegard Greinix; Felix Keil; Barbara Schneider; Michael Sandherr; Gesine Bug; Johanna Tischer; Georg Ledderose; Michael Hallek; Wolfgang Hiddemann; Hans-Jochem Kolb
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

Review 10.  Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature.

Authors:  A Mele; P J Paterson; H G Prentice; P Leoni; C C Kibbler
Journal:  Bone Marrow Transplant       Date:  2002-04       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.